Core Insights - Asset management institutions have shown a decline in enthusiasm for researching listed companies in Q3, with a 24.8% decrease in the number of companies surveyed compared to the previous quarter [1] - In contrast, during Q2, there was a significant increase of 49.31% in the number of companies surveyed as the market experienced a period of stagnation [1] - The focus of asset management institutions remains on technology stocks, with a growing interest in pharmaceutical and medical stocks [2] Group 1: Research Activity - In the first three quarters, insurance asset management companies conducted 7,687 surveys on 5,850 individual stocks, with a majority focused on Shenzhen Main Board and Sci-Tech Innovation Board, accounting for 26.92% and 25.91% respectively [2] - The most active insurance asset management company, Taikang Asset, surveyed 860 companies, focusing primarily on the Shanghai Main Board [2] - Broker asset management companies surveyed 4,216 times, with 3,321 individual stocks, showing a preference for high-growth potential and technology-intensive companies [2][3] Group 2: Sector Preferences - In Q3, the Sci-Tech 50 index rose by 49.02%, significantly outperforming the Shanghai and Shenzhen 300 index, which increased by 17.9% [4] - Insurance asset management companies surveyed 600 companies on the Sci-Tech Innovation Board in Q3, making it the most surveyed sector, followed by the Shenzhen Main Board [4] - The most favored stocks among research institutions in Q3 included Mindray Medical, with 538 institutions conducting surveys, followed by Huichuan Technology and Maiwei Biomedical [5]

证券代码：688062 证券简称：迈威生物 公告编号：2025-061 迈威（上海）生物科技股份有限公司 关于 2025 年度第一期定向科技创新债券发行结果的 公告 本 期 发 行 定 向 科 技 创 新 债 券 的 相 关 文 件 已 在 中 国 货 币 网 （www.chinamoney.com.cn）、上海清算所网站（www.shclearing.com.cn）刊登。 经通过"信用中国"网站（www.creditchina.gov.cn）核查，截至本公告日， 公司不属于失信责任主体。 特此公告。 2025 年 9 月 11 日，公司收到交易商协会出具的《接受注册通知书》（中市 协注〔2025〕PPN310 号），交易商协会决定接受公司科技创新债券注册，注册 基础品种为定向债务融资工具，注册金额为 5 亿元，注册额度自通知书落款之日 起 2 年内有效，在注册有效期内可分期定向发行科技创新债券。 公司 2025 年度第一期定向科技创新债券于 2025 年 10 月 15 日完成发行，募 集资金已于 2025 年 10 月 16 日到账。现将发行结果公告如下： | 债券全称 | 迈威（上海）生物科技股份 有限 ...

Core Insights - The article highlights the active engagement of private equity firms in conducting research on listed companies, with a total of 2712 private equity firms researching 1490 stocks, resulting in 18,500 research instances since the beginning of the second half of the year [1][4]. Group 1: Private Equity Research Activity - The most active private equity firms include Shenzhen Shangcheng Asset Management with 291 research instances and Guangdong Zhengyuan Private Equity with 217 instances, covering 271 and 199 stocks respectively [2][1]. - Other notable firms include Qingli Investment and Pankin Investment, with 143 and 142 research instances respectively, both covering 130 stocks [1][2]. - A total of 45 private equity firms conducted between 50 to 100 research instances during the same period [1]. Group 2: Focus Areas of Research - The TMT (Technology, Media, and Telecommunications) sector is a primary focus, with 384 stocks researched, accounting for 25.77% of the total [4]. - Within the TMT sector, the electronics and computer industries had 207 and 118 stocks researched respectively, while the telecommunications and media sectors had fewer stocks at 38 and 21 [4]. - Other sectors with significant research interest include machinery and pharmaceuticals, with 200 and 179 stocks researched respectively [5]. Group 3: Market Performance - The average increase in the 31 Shenwan primary industry indices since the beginning of the second half of the year is 15.13% [5]. - Specific indices in the TMT sector, such as telecommunications, electronics, and power equipment, have seen increases exceeding 40% [5]. - The machinery and basic chemicals sectors also performed well, with increases of 24.16% and 16.47% respectively [5]. Group 4: Stock Performance - Among the 1490 stocks researched, 558 stocks saw price increases between 0%-20%, while 406 stocks increased between 20%-50%, together making up 64.7% of the total [7]. - A total of 44 stocks experienced price increases exceeding 100%, and 154 stocks increased between 50%-100% [7]. - Five stocks attracted over 100 private equity firms for research, including Maiwei Biotech and Mindray Medical, with respective price increases of 66.97% and 3.14% [8].

10月16日，迈威生物盘中上涨2.18%，截至10:16，报48.25元/股，成交2.26亿元，换手率2.34%，总市值 192.81亿元。 资金流向方面，主力资金净流入781.04万元，特大单买入1292.29万元，占比5.71%，卖出1211.61万元， 占比5.35%；大单买入5781.67万元，占比25.53%，卖出5081.31万元，占比22.44%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌药物、抗 癌治癌、创新药、眼科概念等。 截至6月30日，迈威生物股东户数1.79万，较上期增加11.66%；人均流通股11379股，较上期减少 10.44%。2025年1月-6月，迈威生物实现营业收入1.01亿元，同比减少12.43%；归母净利润-5.51亿元， 同比减少23.90%。 机构持仓方面，截止2025年6月30日，迈威生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股474.26万股，为新进股东。兴全合润混合A（163406）位居第五大流通股东，持股339.00 万股，为新进股东。鹏华医药科技股票A（001230）位居第六大流通股东，持股 ...

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 10月15日，迈威生物盘中上涨2.05%，截至10:03，报45.33元/股，成交1.10亿元，换手率1.20%，总市值 181.14亿元。 资金流向方面，主力资金净流入607.26万元，特大单买入613.51万元，占比5.57%，卖出235.49万元，占 比2.14%；大单买入3098.47万元，占比28.13%，卖出2869.24万元，占比26.05%。 迈威生物今年以来股价涨124.41%，近5个交易日跌7.72%，近20日跌9.74%，近60日涨46.94%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌治癌、抗 癌药物、眼科概念、创新药等。 截至6月30日，迈威生物股东户 ...

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., announced the presentation of clinical research data for its antibody-drug conjugate 7MW3711 at the 2025 European Society for Medical Oncology (ESMO) conference, highlighting its potential in treating advanced solid tumors with promising efficacy and safety profiles [1][2][3]. Group 1: Drug Overview - 7MW3711 is an antibody-drug conjugate targeting B7-H3, designed for advanced malignant solid tumors, with B7-H3 being overexpressed in many cancer types but low in normal tissues [2][3]. - The drug exhibits structural stability, high purity, and ease of industrial scaling, utilizing a novel camptothecin-based toxin that shows superior anti-tumor activity compared to similar drugs [3][4]. - The clinical trial data presented at ESMO indicates that among 54 evaluable patients receiving a dose of 4.0 mg/kg or higher, 19 patients achieved partial or complete responses [1][4]. Group 2: Clinical Trial Results - As of September 15, 2025, a total of 74 patients were enrolled in the I/II phase clinical study, with no dose-limiting toxicities observed and the maximum tolerated dose not yet reached [3][4]. - In the 4.0 mg/kg or higher dose group, the objective response rate (ORR) for esophageal cancer patients was 42.9%, with a disease control rate (DCR) of 100% [1][4]. - For lung cancer patients in the same dose group, the ORR for small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) was 50.0% and 38.5%, respectively, with DCRs of 90.0% and 92.3% [1][4].

Group 1 - The core point of the article is that Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 [2] Group 2 - The approval signifies a significant step forward for the company's research and development efforts in the pharmaceutical sector [2] - The clinical trial approval is expected to enhance the company's position in the competitive biotech industry [2] - This development may lead to potential future revenue streams if the clinical trials are successful [2]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911, marking a significant advancement in its drug development pipeline [1] Group 1: Drug Development - The clinical trial approval pertains to 7MW4911, which features a highly engineered design integrating three core components: a CDH17 high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] - The drug is designed to overcome multi-drug resistance mechanisms, enhancing its potential effectiveness in cancer treatment [1] Group 2: Mechanism of Action - MF-6 is noted for its excellent plasma stability, controllable drug release, and strong bystander effect, which significantly enhances its anti-tumor activity [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various gastrointestinal cancers [1] Group 1: Company Developments - The clinical trial approval for 7MW4911 marks a significant milestone for the company, showcasing its capabilities in developing novel therapeutics based on its proprietary IDDC™ antibody conjugation technology platform [1] - 7MW4911 specifically targets calcium adhesion protein 17 (CDH17), which is overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, indicating its potential for precision intervention in these malignancies [1] Group 2: Industry Context - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, highlighting its relevance in the oncology landscape [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, making it an ideal target for therapeutic intervention in gastrointestinal malignancies [1]